ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1484

B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Abstract Number: 1562

B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
Abstract Number: 0982

B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach
Abstract Number: 0498

Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Abstract Number: 1746

Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Abstract Number: 1396

Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
Abstract Number: 1763

Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus 
Abstract Number: 0603

Barriers and Potential Solutions in the Recruitment and Retention of Older Patients in Clinical Trials – Lessons Learned from Six Large Multi-center Randomized Controlled Trials
Abstract Number: 1168

Barriers to Effectiveness of Non-surgical Treatments for Knee Osteoarthritis in a Diverse Racial/Ethnic Population: A Nominal Group Qualitative Study
Abstract Number: 1642

Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
Abstract Number: 0214

Baseline Cam or Pincer Morphology Is Associated with Loss of Quantitative Joint Space Width at the Hip: The Johnston County Osteoarthritis Project
Abstract Number: 0766

Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Abstract Number: 0934

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-Radiographic Axial Spondylarthritis Patients Through 52 Weeks: Data from 3 Phase III, Randomized, Controlled Trials
Abstract Number: 0821

Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
Abstract Number: 0807

Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
Abstract Number: 1225

Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA
Abstract Number: 1444

Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
Abstract Number: 0540

Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Abstract Number: 1727

Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes
Abstract Number: 1461

Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Abstract Number: 1295

Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
Abstract Number: 0277

Best Cardiovascular Risk Algorithm to Predict Abnormalities in Left Ventricular Geometry in Rheumatoid Arthritis Patients
Abstract Number: 1175

Best Practice Guidelines for Telehealth in Rheumatology: An Initiative by the Arab League of Associations for Rheumatology
Abstract Number: 1180

Better Websites, Better Match: Assessing Quality of Rheumatology Fellowship Websites
Abstract Number: 1747

BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 1338

Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Abstract Number: 0491

Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Abstract Number: 0922

Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Abstract Number: 1885

Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Abstract Number: 0818

Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Abstract Number: 0490

Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
Abstract Number: 1240

Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Abstract Number: 0915

Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis
Abstract Number: 0817

Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
Abstract Number: 0573

Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Abstract Number: 0870

Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
Abstract Number: 1774

Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
Abstract Number: 1769

BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects
Abstract Number: 0125

Body Mass Composition in Post-menopausal Women with Fibromyalgia: Preliminary Results from a Cross-sectional Monocentric Study
Abstract Number: 1322

Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
Abstract Number: 0447

Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor
Abstract Number: 0171

Bone Erosions and Osteophytes in Premenopausal Women with Long-standing Rheumatoid Arthritis: Association with Systemic Bone Involvement Using HR-pQCT
Abstract Number: 0852

Bone Marrow Lesion Segmentation Using Synthetic Data and Deep Learning Models
Abstract Number: 0448

Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as Predictor of Incident Fracture in Rheumatic Disease Patients on Long-term Glucocorticoid- a Five-year Longitudinal Study
Abstract Number: 1859

Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Abstract Number: L16

Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Abstract Number: 0754

Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
Abstract Number: 0625

Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes
Abstract Number: 1173

Bringing Reproductive Health Guidelines into Fellowship Training: A National Survey of Adult and Pediatric Rheumatology Fellows and Program Directors to Assess Educational Need and Inform Curriculum Development
Abstract Number: 0035

Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1617

Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].